Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Progress in Nanotechnology-Based Therapeutic Strategies
share announcement

Progress in Nanotechnology-Based Therapeutic Strategies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 1448

Special Issue Editors

Dr. Ambra Del Grosso

E-Mail Website
Guest Editor
NEST (National Enterprise for nanoScience and nanoTechnology), Istituto Nanoscienze-CNR and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy
Interests: neurodegenerative lysosomal disease; nanovector-mediated enzyme; Krabbe disease
Dr. Mariacristina Gagliardi

E-Mail Website
Guest Editor
NEST, Istituto Nanoscienze-CNR and Scuola Normale Superiore, Piazza San Silvestro, 56127 Pisa, Italy
Interests: biomaterial; nanomaterials

Special Issue Information

Dear Colleagues,

This Special Issue will focus on the latest advancements in nanotechnology-based therapeutic strategies, emphasizing their transformative impact on modern medicine. Nanotechnology has become a key tool in developing innovative therapeutic solutions, providing unparalleled opportunities to enhance the precision, efficacy, and safety of treatments for a wide range of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, infectious diseases, and lysosomal storage disorders.

Key topics in this Special Issue include the use of nanoparticles for targeted drug delivery, enabling drugs to reach specific tissues or cells with minimal off-target effects, thus reducing toxicity and improving therapeutic outcomes. In addition, we will explore nanomaterial-based therapies, such as nanostructures functioning as therapeutic agents or facilitating regenerative medicine, tissue engineering, and gene therapy. Other relevant areas include the integration of nanotechnology with biochemical analyses for monitoring treatment efficacy and omics approaches (e.g., genomics, proteomics, and metabolomics) to understand disease mechanisms and therapeutic responses at the molecular level.

This Special Issue will cover both preclinical and clinical advances, highlighting novel nanotechnology-based platforms, innovative biomaterials, and strategies to overcome biological barriers. We invite submissions on topics ranging from the design and synthesis of novel nanomaterials to their applications in personalized medicine, biochemical diagnostics, and real-time therapeutic monitoring.

Contributions that present breakthrough findings, review the current state of the field, or explore future directions of nanotechnology in medicine are highly encouraged. This Special Issue aims to offer a comprehensive view of how nanotechnology is driving the evolution of therapeutic strategies, omics integration, and improving patient outcomes.

Dr. Ambra Del Grosso
Dr. Mariacristina Gagliardi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology-based therapies
  • targeted drug delivery
  • nanoparticles
  • nanostructures
  • cancer treatment
  • cardiovascular diseases
  • neurodegenerative diseases
  • infectious diseases
  • lysosomal storage disorders
  • regenerative medicine
  • tissue engineering
  • gene therapy
  • biochemical diagnostics
  • omics approaches
  • biological barriers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 1438 KiB  
Article
Nanosurgery and Bioengineered Regenerative Protocols for the Treatment of Hip Osteoarthritis: A Double-Blind Randomized Controlled Trial as an Alternative to Surgical Hip Replacement
by Cezary Wasilczyk and Bartosz Wasilczyk
Biomedicines 2025, 13(4), 987; https://doi.org/10.3390/biomedicines13040987 - 17 Apr 2025
Viewed by 325
Abstract
Introduction: Hip osteoarthritis (HOA) significantly affects mobility and quality of life, with total hip arthroplasty (THA) being a common treatment. However, complications and increasing revision rates highlight the need for alternative approaches. This study evaluates the efficacy of ultrasound-guided nanosurgery and bioengineering treatment [...] Read more.
Introduction: Hip osteoarthritis (HOA) significantly affects mobility and quality of life, with total hip arthroplasty (THA) being a common treatment. However, complications and increasing revision rates highlight the need for alternative approaches. This study evaluates the efficacy of ultrasound-guided nanosurgery and bioengineering treatment (NSBT) compared to non-standardized platelet-rich plasma (PRP) treatment for patients with symptomatic HOA. Methods: A double-blind, randomized trial included 38 patients referred for THA, divided into two groups. The study group received NSBT with modified PRP enriched with somatotropin and Strophanthus kombe, while the control group received PRP and hyaluronic acid injections without a standardized protocol. Treatments were guided by ultrasound, and outcomes were assessed using the Visual Analog Scale (VAS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), Harris Hip Score (HHS), and range of motion (RoM) evaluations over 12 months. Results: The study group showed significant improvements in all clinical outcomes, including reductions in VAS scores from 7.8 to 0.2 (p < 0.0001) and WOMAC scores from 76.2 to 10.5 (p < 0.0001). The HHS improved from 56.4 to 93.0, and RoM showed substantial gains in flexion, external rotation, and internal rotation (all p < 0.001). The control group demonstrated less pronounced improvements. Conclusions: NSBT offers a safe and effective alternative for managing HOA, significantly reducing pain and improving joint function while potentially delaying or avoiding the need for THA. Further long-term studies are warranted to confirm these findings. Full article
(This article belongs to the Special Issue Progress in Nanotechnology-Based Therapeutic Strategies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

35 pages, 2111 KiB  
Review
Small Biological Fighters Against Cancer: Viruses, Bacteria, Archaea, Fungi, Protozoa, and Microalgae
by Pathea Shawnae Bruno, Peter Biggers, Niyogushima Nuru, Nicholas Versaci, Miruna Ioana Chirila, Costel C. Darie and Anca-Narcisa Neagu
Biomedicines 2025, 13(3), 665; https://doi.org/10.3390/biomedicines13030665 - 8 Mar 2025
Viewed by 810
Abstract
Despite the progress made in oncological theranostics, cancer remains a global health problem and a leading cause of death worldwide. Multidrug and radiation therapy resistance is an important challenge in cancer treatment. To overcome this great concern in clinical practice, conventional therapies are [...] Read more.
Despite the progress made in oncological theranostics, cancer remains a global health problem and a leading cause of death worldwide. Multidrug and radiation therapy resistance is an important challenge in cancer treatment. To overcome this great concern in clinical practice, conventional therapies are more and more used in combination with modern approaches to improve the quality of patients’ lives. In this review, we emphasize how small biological entities, such as viruses, bacteria, archaea, fungi, protozoans, and microalgae, as well as their related structural compounds and toxins/metabolites/bioactive molecules, can prevent and suppress cancer or regulate malignant initiation, progression, metastasis, and responses to different therapies. All these small biological fighters are free-living or parasitic in nature and, furthermore, viruses, bacteria, archaea, fungi, and protozoans are components of human and animal microbiomes. Recently, polymorphic microbiomes have been recognized as a new emerging hallmark of cancer. Fortunately, there is no limit to the development of novel approaches in cancer biomedicine. Thus, viral vector-based cancer therapies based on genetically engineered viruses, bacteriotherapy, mycotherapy based on anti-cancer fungal bioactive compounds, use of protozoan parasite-derived proteins, nanoarchaeosomes, and microalgae-based microrobots have been more and more used in oncology, promoting biomimetic approaches and biology-inspired strategies to maximize cancer diagnostic and therapy efficiency, leading to an improved patients’ quality of life. Full article
(This article belongs to the Special Issue Progress in Nanotechnology-Based Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop